Results
1 -
10 of
24Substrate-Envelope-Guided Design of Drugs with a High Barrier to the Evolution of Resistance, Handbook of Antimicrobial Resistance A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail, European Journal of Clinical Pharmacology Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate, European Journal of Clinical Pharmacology Hepatitis C therapyu2014the future looks bright, European Journal of Clinical Microbiology & Infectious Diseases A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations, Nature Communications Non-interferon Therapies for Hepatitis C, Current Hepatitis Reports What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?, Current Gastroenterology Reports NS5A Inhibitors, Current Hepatitis Reports Second Generation Protease Inhibitors and Nucleotide Inhibitors, Current Hepatitis Reports Treatment of chronic hepatitis C: Anticipated impact of resistance in patients treated with protease inhibitors, Current Gastroenterology Reports